NCT04566770已完成2 期
A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 480
- 试验地点
- 1
- 主要终点
- Safety indexes of adverse reactions
研究概览
简要总结
This study is a randomized, double-blind, placebo -controlled IIb clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in people 6 years old and above and .
详细描述
This is a phase IIb clinical trial to evaluate safety and immuogenicity of Ad5-nCoV developed by Cansino and Beijing Institute of Biotechnology in health people aged 6 years old and above.
The study will be double-blind, placebo-controlled trial with participants randomly allocated 2:1 to placebo and experimental vaccine .
The immunization schedule is two doses intramuscular injections (deltoid).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 18 to 55 years old in MID group; aged 6-17 years old in MIN group; aged 56 years and above in OLD group; aged in EBO group is not limited.
- •Able to understand the content of informed consent and willing to sign the informed consent
- •Able and willing to complete all the secluded study process during the whole 6 months study follow-up period.
- •Negative in HIV diagnostic test.
- •Negative in serum antibodies (IgG and IgM) screening of COVID-
- •Axillary temperature ≤37.0°C.
- •General good health as established by medical history and physical examination.
排除标准
- •Family history of seizure, epilepsy, brain or mental disease
- •Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past.
- •Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months
- •Any acute fever disease or infections.
- •History of SARS
- •Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease.
- •Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.
- •Hereditary angioneurotic edema or acquired angioneurotic edema Urticaria in last one year
- •No spleen or functional spleen.
- •Platelet disorder or other bleeding disorder may cause injection contraindication
- •Faint at the sight of needles.
- •Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months.
- •Prior administration of blood products in last 4 months
- •Prior administration of other research medicines in last 1 month
- •Prior administration of attenuated vaccine in last 1 month
- •Prior administration of inactivated vaccine in last 14 days
- •Current anti-tuberculosis prophylaxis or therapy
- •According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent.
结局指标
主要结局
Safety indexes of adverse reactions
时间窗: within 14 days post each vaccination
Occurrence of adverse reactions post vaccination
Immunogencity indexes of GMT
时间窗: Day 28 post the second vaccination
Evaluate the Geometric mean titer (GMT) of IgG antibody
Immunogencity indexes of neutralizing antibody
时间窗: Day 28 post the second vaccination
Evaluate the Geometric mean titer (GMT) of neutralizing antibody
次要结局
- Immunogencity indexes of GMT(Day 28 post the first vaccination, pre the second vaccination ,Month 6 post the second vaccination)
- Safety indexes of Hematological examination measures（Hemoglobin, WBC）(pre-vaccination, day 4 post each vaccination)
- Safety indexes of SAE(Within 6 months post the second vaccination)
- Safety indexes of Blood routine measures(ALT, AST)(pre-vaccination, day 4 post each vaccination)
- Safety indexes of adverse events(Day 0-7,0-14,0-28 post each vaccination)
- Immunogencity indexes of neutralizing antibody(Day 28 post the first vaccination, pre the second vaccination ,Month 6 post the second vaccination)
- Immunogencity indexes of cellular immune(Day 28 post the first vaccination, pre and day 28 post the second vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for InhalationCOVID-19NCT04840992CanSino Biologics Inc.840
已完成
2 期
Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIVCovid19NCT05005156Fundación Huésped155
Unknown
1 期
A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.Esophageal CancerNCT04460066Lee's Pharmaceutical Limited70
已完成
2 期
Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and AdolescentsCOVID-19NCT04884685Sinovac Life Sciences Co., Ltd.500
已完成
2 期
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.Diabetes Mellitus, Type 2NCT06579105AstraZeneca406